Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
NCT ID: NCT05503953
Last Updated: 2022-08-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
306 participants
INTERVENTIONAL
2022-09-05
2024-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension
NCT04686643
Clinical Trial to Evaluate the Antihypertensive Effect of AGSCT101 in Patient With Hypertension
NCT01413048
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy
NCT05931224
A Study to Evaluate the Efficacy and Safety of AD-224
NCT06291207
Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients
NCT05199129
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AGSAVI
AGSAVI
Uptitation
AGLS
AGLS
Uptitration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AGSAVI
Uptitation
AGLS
Uptitration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patient who takes antihypertensive drug
* 140mmHg \<= MSSBP \< 200mmHg
* 130mmHg \<= MSSBP \< 200mmHg at or before visit 1(In high-risk patients)
* patient who doesn't take antihypertensive drug
* 160mmHg \<= MSSBP \< 200mmHg
* Hypertension patient who satisfied below condition at Visit 2.
* 140mmHg \<= MSSBP \< 200mmHg at Visit 2
* 130mmHg \<= MSSBP \< 200mmHg at or before Visit 1(In high-risk patients)
Exclusion Criteria
* Patient with 20mmHg\>= of difference in MSSBP or 10mmHg\>= of difference in MSDBP between 2 times of BP measuring at Visit 1
* Patient with MSDBP \>= 120mmHg at Visit 1 or 2
* Patient with secondary hypertension(including past medical history)
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daehwa Pharmaceutical Co., Ltd.
INDUSTRY
Ahn-Gook Pharmaceuticals Co.,Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AG-1705_P3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.